登录  注册
神经病学术中心首页 > 期刊 > 全球精选文摘

神经病学术中心

阿司匹林对结直肠癌发生率和死亡率的长期影响:5项随机试验随访20年的结果

Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials

来源:国际医学期刊 发布时间:2012-5-8
作者:Rothwell Wilson Elwin
期刊: LANCET NEUROL2012年1月期卷

Background:

High-dose aspirin (≥500mg daily) reduces long-term incidence of colorectal cancer, but adverse effects might limit its potential for long-term prevention. The long-term effectiveness of lower doses (75–300mg daily) is unknown. We assessed the effects of aspirin on incidence and mortality due to colorectal cancer in relation to dose, duration of treatment, and site of tumour.

Methods:

We followed up four randomised trials of aspirin versus control in primary (Thrombosis Prevention Trial, British Doctors Aspirin Trial) and secondary (Swedish Aspirin Low Dose Trial, UK-TIA Aspirin Trial) prevention of vascular events and one trial of different doses of aspirin (Dutch TIA Aspirin Trial) and established the effect of aspirin on risk of colorectal cancer over 20years during and after the trials by analysis of pooled individual patient data.

Results:

In the four trials of aspirin versus control (mean duration of scheduled treatment 6·0years), 391 (2·8%) of 14033 patients had colorectal cancer during a median follow-up of 18·3years. Allocation to aspirin reduced the 20-year risk of colon cancer (incidence hazard ratio [HR] 0·76, 0·60–0·96, p="0"·02; mortality HR 0·65, 0·48–0·88, p="0"·005), but not rectal cancer (0·90, 0·63–1·30, p="0"·58; 0·80, 0·50–1·28, p="0"·35). Where subsite data were available, aspirin reduced risk of cancer of the proximal colon (0·45, 0·28–0·74, p="0"·001; 0·34, 0·18–0·66, p="0"·001), but not the distal colon (1·10, 0·73–1·64, p="0"·66; 1·21, 0·66–2·24, p="0"·54; for incidence difference p="0"·04, for mortality difference p="0"·01). However, benefit increased with scheduled duration of treatment, such that allocation to aspirin of 5years or longer reduced risk of proximal colon cancer by about 70% (0·35, 0·20–0·63; 0·24, 0·11–0·52; both p<0·0001) and also reduced risk of rectal cancer (0·58, 0·36–0·92, p="0"·02; 0·47, 0·26–0·87, p="0"·01). There was no increase in benefit at doses of aspirin greater than 75mg daily, with an absolute reduction of 1·76% (0·61–2·91; p="0"·001) in 20-year risk of any fatal colorectal cancer after 5-years scheduled treatment with 75–300mg daily. However, risk of fatal colorectal cancer was higher on 30mg versus 283mg daily on long-term follow-up of the Dutch TIA trial (odds ratio 2·02, 0·70–6·05, p="0"·15).

Interpretation:

Aspirin taken for several years at doses of at least 75mg daily reduced long-term incidence and mortality due to colorectal cancer. Benefit was greatest for cancers of the proximal colon, which are not otherwise prevented effectively by screening with sigmoidoscopy or colonoscopy (Table 3).

Table 3: Effect of Aspirin (75–1200mg) Versus Control on Long-Term Risk of Colorectal Cancer

顶一下(0

发表评论

学科影响因子排名more

 会议回顾 more

  • 第27届欧洲神经心理药理学学院大会...

  • 《阿尔茨海默病与痴呆(中文版)》启...

  • 深化卒中防治 践行规范、推广、指导

 热门病例 more

 热门指南  more

Elsevier中国网站
爱唯医学网
爱思唯尔科技部
NursingChina
柳叶刀中文版
大通医疗决策
医大爱思唯尔
Elsevier医学数据库
CK
Journal Consult
Procedures_CONSULT
ClinicalPharmacologyLogo
3D Interact Anatomy
Mosby’s Nursing Consult
NursingChina
Science Direct